JLHL · NSE
Jupiter Life Line Hospitals Limited
₹280.05
+0.83% (+₹2.3)
Prev. close
₹277.75
Volume
2,40,514
Delivery %
56.3%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Jupiter Life Line Hospitals Limited
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel brand in Thane. The company was incorporated in 2002 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Ankit Ajay Thakker
Headquarters
Mumbai
Employees
3,002
Website
jupiterhospital.comExchange
View on NSE ↗Key stats
Market cap
₹9,180.88 Cr
P/E ratio (TTM)
49.0
Dividend yield
0.07%
EPS (TTM)
₹5.72
Beta (1Y · daily vs NIFTY 50)
0.24
Beta (5Y · monthly vs NIFTY 50)
0.59
Shares float
12.58 Cr
EPS · quarter ended Jun 2026
₹1.14
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹892.54 Cr | ₹1,069.50 Cr | ₹1,261.55 Cr | ₹1,499.79 Cr | |
| EBITDA | ₹206.01 Cr | ₹264.14 Cr | ₹325.24 Cr | ₹385.63 Cr |
| ₹72.91 Cr | ₹176.61 Cr | ₹193.20 Cr | ₹194.01 Cr | |
| Diluted EPS | ₹2.22 | ₹5.73 | ₹5.89 | ₹5.92 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹985.53 Cr | ₹1,281.33 Cr | ₹1,935.75 Cr | ₹2,383.13 Cr | |
| ₹468.63 Cr | ₹0 | ₹393.15 Cr | ₹584.24 Cr | |
| Stockholders' equity | ₹365.69 Cr | ₹1,169.04 Cr | ₹1,356.24 Cr | ₹1,544.08 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹117.17 Cr | ₹114.52 Cr | ₹266.74 Cr | ₹267.71 Cr | |
| Investing cash flow | ₹-103.57 Cr | ₹-246.14 Cr | ₹-497.33 Cr | ₹-441.93 Cr |
| ₹17.50 Cr | ₹128.16 Cr | ₹296.71 Cr | ₹136.47 Cr | |
| Capital expenditure | ₹-77.24 Cr | ₹-85.30 Cr | ₹-327.59 Cr | ₹-501.85 Cr |
| End cash position | ₹134.46 Cr | ₹23.01 Cr | ₹92.52 Cr | ₹54.76 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 23–Jun 26(13Q) |
|---|---|
| Promoter | 40.91% |
| Public | 59.09% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Jupiter Life Line Hospitals Limited | ₹9,105.48 Cr | ₹280.05 | 48.5 | 5.90 | 12.6% | 0.38 | +15.2% | -80.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
3 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Jupiter Hospitals Q2 FY27 Data Preview
Jupiter Life Line Hospitals' Q2 FY27 results date is unconfirmed, with the company yet to file a board meeting intimation as of September 16, 2026. Indian regulations require results to be published by November 14, 2026. The upcoming quarter will be compared against Q2 FY26, which reported a profit of Rs 57.00 crore.
Jupiter Life Line Hospitals revenue up 16.4%; profit dips 14.6% in Q1FY27
medicalbuyer.co.in · 2 months ago